Pharmacology and Toxicology

Print Page Print   EmailEmail   Bookmark Page Bookmark   RSS Feeds RSS

 

 

John A. Auchampach, PhD
Professor

Medical College of Wisconsin (1992)
PhD Pharmacology and Toxicology

Molecular Pharmacology
Cardiovascular Pharmacology

Phone: 414 456-5643
Fax: 414-456-6545
jauchamp@mcw.edu

 

John A. Auchampach, Ph.D.


Research Interests:

Research interests in my laboratory center around two general areas.  The first deals with the molecular and functional characterization of receptors for the endogenous nucleoside adenosine.  The second addresses the potential for cardiac regeneration following myocardial infarction using embryonic stem cells.

Techniques in use:

1.  Molecular biology - receptor cloning and expression, radioligand binding, siRNA, real-time PCR, western immunoblotting, ELISA, electomobility shift assay

2.  Cell biology – isolation and functional analysis of mouse macrophages, neutrophils, endothelial cells, and lymphocytes

3.  Mouse genetics - generation of global and tissue-specific gene 'knock-out' mouse lines, bone marrow transplantation

4.  Mouse disease models - In vivo mouse infarction model, aortic banding model of cardiac hypertrophy, Langendorf-perfused isolated mouse heart model of ischemia/reperfusion injury

5.  Mouse physiology – systemic blood pressure and left ventricular pressure measurements, echocardiography

Summary:

Molecular and Functional Charcterization of Adenosine Receptors.   Adenosine is an important signaling molecule that exerts effects in essentially every organ system by interacting with four G protein-coupled receptors designated A1, A2A, A2B, and A3.  Our laboratory employs modern techniques of molecular pharmacology to understand adenosine receptor function at both the molecular and physiological level.  Current emphasis is focused on the two most recently identified receptors for adenosine, the A2B and A3 receptors.  Studies underway in the laboratory include cloning and pharmacological characterization of adenosine receptors, analysis of adenosine receptor signaling in cells, and functional characterization of adenosine receptors in mouse models of pathogenesis using genetically modified mice.

 

We are currently assessing the importance of the newly discovered A3 adenosine receptor during myocardial infarction.  Our laboratory has previously shown that administering agonists with high affinity for the A3 adenosine receptor reduces injury from myocardial ischemia and reperfusion in dogs, rabbits, and mice if given prior to the ischemic event or if given only during reperfusion.  Using global and cardiac-specific A3 adenosine receptor gene 'knock-out' mice (Cre recombinase-LoxP strategy) and bone marrow chimeric mice lacking the expression of the A3 adenosine receptor in bone marrow-derived cells, we are testing the hypothesis (see Figure 1) that activating the A3 adenosine receptor in cardiomyocytes protects against ischemic injury by improving mitochondrial function and reducing apoptosis, whereas activating the A3 adenosine receptor in immune cells during reperfusion is protective by suppressing inflammatory responses.  Correlative molecular/cellular studies are underway to examine the function of the A3 adenosine receptor in specific populations of inflammatory cells isolated from the mouse including neutrophils, monocytes, macrophages, and endothelial cells. 

Cardiac Regeneration Using Embryonic Stem Cells.  Embryonic stem cells have the potential to differentiate into any cell type in the body and are therefore attractive for application to tissue regeneration.  We and others have shown that injecting small numbers of pluripotent mouse embryonic stem cells results in cell engraftment and functional improvement of post-infarcted mouse myocardium (Figure 2), although the mechanism for improvement is uncertain and the potential for tumorogenesis remains a significant concern.  In collaboration with the Lough lab (Cell Biology, Neurobiology and Anatomy), Misra lab (Biochemistry), and others, we are addressing the hypothesis that transplantation of mouse embryonic stem cells pre-differentiated in cell culture to specific cardiac lineages (i.e., cardiomyocytes, vascular precursor cells) will reduce the potential for tumor formation and improve functional recovery due to the incorporation of functional, electrically coupled mycoytes into the myocardium. 

 


Recent Publications

Auchampach JA, Gross GJ.  (2007) Reperfusion injury:  Does it exist?  Journal of Molecular and Cellular Cardiology  42:12-18.

Ge ZD, Peart JN, Kreckler LM, Wan TC, van der Hoeven D, Gross GJ, Jacobson MA, Auchampach JA (2006).  Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methycarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.  Journal of Pharmacology and Experimental Therapeutics 319:1200-1210.

Nelson TJ, Ge ZD, Van Orman J, Barron M, Rudy-Reil D, Hacker TM, Misra R, Auchampach JA, Lough J.  (2006).  Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells.  Anatomical Record 288A:  1216-1224.

Carrier EJ, Auchampach JA, Hillard CJ.  Inhibition of the equilibrative nucleoside transporter by cannabidiol:  A novel mechanism of cannabinoid immunosuppression.  Proceedings of the National Academy of Sciences USA 103:7895-7900.

Kreckler LM, Wan TC, Ge ZD, Auchampach JA.  Adenosine inhibits TNF-a release from mouse peritoneal macrophages via A2A and A2B, but not A3 adenosine receptors.  Journal of Pharmacology and Experimental Therapeutics 317: 172-180.

Gross ER, Peart JN, Hsu AK, Auchampach JA, Gross GJ (2005).  Extending the cardioprotective window by a novel d opioid agonist fentanyl isothiocyanatevia the phosphoinositol-3 kinase pathway.  American Journal of Physiology 288:  H2744-H2749.

Fabritz L, Kirchhof P, Fortmüller L, Auchampach JA, Baba HA, Breithardt G, Neumann J, Boknik P, Schmitz W. (2004) Gene dose-dependent atrial arrhythmias, heart block and atrial brady-cardiomyopathy in mice overexpressing the A3 adenosine receptor. Cardiovascular Research 62:500-508.

Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ (2003)  The A3 adenosine receptor agonist IB-MECA reduces ischemia-reperfusion injury in dogs.  American Journal of Physiology 285:  H607-H613.

Black RG, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R, Auchampach JA (2002). Gene dosage dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circulation Research 91: 165-172.

webmaster@mcw.edu
© 2007 Medical College of Wisconsin
Page Updated 02/14/2008